News Takeda Pharmaceutical Company Limited Mexican S.E.

Equities

TAK N

US8740602052

End-of-day quote Mexican S.E. Other stock markets 07:00:00 2024-03-12 pm EDT			5-day change	1st Jan Change
240.5 ^MXN	-1.84%		-.--%	+0.33%

Jun. 14	Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	MT
Jun. 14	Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Takeda Signs Option Agreement with Ascentage to License Leukemia Drug	Jun. 14	MT
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	Jun. 14	BU
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor	Jun. 14	CI
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees	Jun. 11	MT
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts	Jun. 11	BU
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K	Jun. 11	PU
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen	Jun. 10	MT
TAKEDA PHARMACEUTICAL : Form 6 K	Jun. 10	PU
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K	Jun. 07	PU
Former Takeda Employee Pleads Guilty to Defrauding Company	Jun. 06	DJ
Takeda Pharmaceutical Unit Partners with HEALWELL AI for Real-World Evidence Analysis of Hereditary Angioedema	Jun. 06	MT
Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India	Jun. 06	MT
Takeda Pharmaceutical - Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan	Jun. 04	AQ
Transcript : Takeda Pharmaceutical Company Limited - Special Call	Jun. 03
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints	Jun. 03	MT
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial	Jun. 03	MT
Takeda Pharmaceutical Company Limited to Present Positive Results from its Phase 2B Trial of TAK-861	Jun. 03	CI
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo	Jun. 03	BU
GSK blood cancer drug nearly halves risk of death in late-stage trial	Jun. 02	RE
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma	Jun. 01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Takeda Pharmaceutical Company Limited Mexican S.E.

Equities

TAK N

US8740602052

Summary

Filters